Time to Onset of Action of Vardenafil: A Retrospective Analysis of the Pivotal Trials for the Orodispersible and Film-Coated Tablet Formulations

Journal of Sexual Medicine

Volumn 8, Issue 10, 2011, Pages 2912-2923

  Debruyne, Frans M J ^a   Gittelman, Marc ^b   Sperling, Herbert ^c   Börner, Matthias ^d   Beneke, Manfred ^d  

^a ANDROS Mannenkliniek   (Netherlands)

^b South Florida Medical Research   (United States)

^c KLINIKEN MARIA HILF GMBH   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

Erectile Dysfunction; Orodispersible Tablet; Phosphodiesterase Type 5 Inhibitor; Time to Onset of Action; Vardenafil

Indexed keywords

PLACEBO; VARDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; ERECTILE DYSFUNCTION; FILM COATING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); ORODISPERSIBLE TABLET FORMULATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEXUAL ENCOUNTER PROFILE; SEXUAL INTERCOURSE; TABLET FORMULATION; TREATMENT OUTCOME;

EID: 80053573655     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02462.x     Document Type: Article

References (13)

1. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID. Chapter 1: The management of erectile dysfunction: An AUA update. J Urol 2005;174:230-9.
2. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU guidelines on erectile dysfunction: An update. Eur Urol 2006;49:806-15.
3. Perelman M, Edwards D. Perceptions of erectile dysfunction therapy and acceptance of an orodispersible phosphodiesterase type 5 formulation among patients and physicians. J Men's Health 2010;7:325.
4. Sperling H, Debruyne F, Boermans A, Beneke M, Ulbrich E, Ewald S. The POTENT I randomized trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010;7:1497-507.
5. Gittelman M, McMahon CG, Rodríguez-Rivera JA, Beneke M, Ulbrich E, Ewald S. The POTENT II randomised trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010;64:594-603.
6. Sperling H, Gittelman M, Norenberg C, Ulbrich E, Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: An integrated analysis of two pivotal trials. J Sex Med 2011;8:261-71.
7. Heinig R, Weimann B, Dietrich H, Böttcher MF. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: Results of three clinical trials. Clin Drug Investig 2011;31:27-41.
8. Axilrod AC. Phosphodiesterase type 5 inhibitor therapy: Identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. Curr Med Res Opin 2007;23:3189-98.
9. Montorsi F, Padma-Nathan H, McCullough A, Brock GB, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo controlled trial. J Urol 2004;172:1036-41.
10. Montorsi F, Hellstrom WJ, Valiquette L, Bastuba M, Collins O, Taylor T, Thibonnier M, Homering M, Eardley I. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004;64:1187-95.
11. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
12. Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003;170:1278-83.
13. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.